Pfizer Inc.

- Pfizer aims to delever as rapidly as possible, having already paid down $4.4 billion in debt year-to-date. - The company is focused on reducing leverage but has not explicitly announced new fundraising through debt or equity. - All options for monetizing assets to support deleveraging and strategic goals are being evaluated, including potential sales of business units or stakes. - No specific plans for new equity raises were mentioned in the call. - Pfizer continues to prioritize financial discipline while supporting ongoing investments in R&D and business development. - The company remains open to strategic business development opportunities, but no immediate fundraising actions were disclosed.

- Pfizer is maintaining a strong focus on R&D efficiency, targeting reduction in less ROI-driven investments while prioritizing productivity and cost control. - The company is actively progressing on its new vaccine candidates, including 4th and 5th generation pneumococcal conjugate vaccines with advanced technology and potentially new adjuvants. - Investments continue in the development and commercialization of innovative oncology assets from the Seagen acquisition, including advancing several programs to Phase III. - Pfizer is expanding mRNA infrastructure globally, in partnership with BioNTech, as a long-term strategic commitment. - The company aims to deleverage rapidly, evaluating monetization of assets including the hospital business and potential earlier full divestment of the Haleon stake, supporting financial flexibility. - Pfizer is prioritizing continued commercial and R&D investments to support growth in new product launches like ABRYSVO and pipeline assets such as oral obesity treatments.

- Pfizer expects continued strong growth from remaining parts of its business beyond COVID-19 products (Page 10). - ABRYSVO shows promising growth, with doubled market share in end customers and retail administration settings; momentum expected to continue into Q4 (Page 10). - The CDK4 inhibitor franchise (Vinda) shows strong growth with new patient starts up 61% YoY and 3% QoQ, but volume growth expected to slow in 2025 due to competitive market landscape (Page 9). - International markets for oncology products continue to grow strongly at 31%, supported by increasing patient treatment rates and reimbursements (Page 9). - RSV vaccine ABRYSVO gaining traction internationally with positive recommendations and reimbursements in multiple major markets; pediatric and adult segments show progress (Page 8). - Pipeline assets, such as obesity treatments with oral candidates, target large markets with significant unmet need, anticipating good market share if successful (Page 3). - Overall operational revenue growth, excluding COVID-19, projected at 9%-11% (Page 3).

- Pfizer raised its full-year 2024 guidance for total revenues to a range of $61 billion to $64 billion. - Operational revenue growth, excluding COVID-19 products, is expected to be 9% to 11%. - COVID-19 product revenues are projected at $10.5 billion ($5 billion for COMIRNATY and $5.5 billion for PAXLOVID). - Adjusted diluted earnings per share (EPS) guidance was increased to $2.75 to $2.95, reflecting top-line growth and cost absorption. - EPS guidance includes an anticipated $0.40 dilution from Seagen acquisition financing costs. - Pfizer aims to continue deleveraging rapidly and is considering monetizing non-core assets to support this. - The company expects strong operational execution and pipeline-driven growth to enable consistent financial performance over time. - Ongoing efficiency plans include a $4 billion expense reduction, enhancing margins without hurting top-line growth.

- For ABRYSVO, Pfizer has worked closely with customers to ensure appropriate stocking in Q3, reflected in Q3 numbers. - Administration volumes for ABRYSVO began in August; volumes during Q3 were lower than the market last year due to factors like COVID vaccine timing and channel dynamics. - Pfizer anticipates continued administration volumes into Q4 for ABRYSVO. - Market share for ABRYSVO in the retail setting has doubled from wholesalers to end customers. - ABRYSVO shipment volume into health systems up 56% compared to the first four weeks of last season. - Positive momentum with a 20% uptake increase in September for the maternal indication of ABRYSVO. - Internationally, Pfizer is making good progress with positive recommendations and reimbursement negotiations underway in multiple countries. - Overall, there is strong performance and expectations for ongoing uptake heading into Q4 and 2025.